drugset / Trial / NCT04557306
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer
Timeline
- Start
- 2020-09-21
- Primary completion
- 2021-10-26
- Completion
- 2021-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vebreltinib | Small molecule | — | Intravenous |